Title:
KRAS_G12V MUTANT ANTIGEN-SPECIFIC TCR AND REDIRECTED CD4 T CELL CO-EXPRESSING SAME AND CD8
Document Type and Number:
WIPO Patent Application WO/2024/093056
Kind Code:
A1
Abstract:
The present invention relates to a T cell receptor (TCR) specifically binding to a KRAS_G12V mutant antigen, a fusion protein or conjugate comprising the TCR, a nucleic acid encoding the TCR and an engineered cell comprising same, and a method for preparing the engineered cell. The present invention further relates to co-expressing an exogenous CD8 molecule and the TCR gene in T cells to enhance the function of T cells. The present invention provides use of the TCR and the genetically engineered cell in the detection, prevention, and/or treatment of cancers related to the KRAS_G12V mutant antigen.
Inventors:
PENG SONGMING (CN)
AN DUO (CN)
ZHONG SHAN (CN)
AN DUO (CN)
ZHONG SHAN (CN)
Application Number:
PCT/CN2023/078124
Publication Date:
May 10, 2024
Filing Date:
February 24, 2023
Export Citation:
Assignee:
NEOWISE BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K14/725; A61K38/17; A61K39/00; A61P35/00; C07K19/00; C12N15/12
Domestic Patent References:
| WO2021083363A1 | 2021-05-06 |
Foreign References:
| CN112300269A | 2021-02-02 | |||
| CN112646024A | 2021-04-13 |
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: